ADVFN Logo

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

ALT Altimmune Inc

8,49
-0,40 (-4,50%)
Avant marché
Dernière mise à jour : 12:34:34
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Altimmune Inc ALT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
-0,40 -4,50% 8,49 12:34:34
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
8,89
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
27/3/202412:00GLOBEAltimmune Announces Positive Lean Mass Preservation Data for..
27/3/202411:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
20/3/202412:30GLOBEAltimmune to Report Fourth Quarter and Full Year 2023..
14/2/202418:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202412:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202417:49EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/1/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202413:30GLOBEAltimmune Announces Presentation of Pemvidutide Clinical..
08/12/202314:35GLOBEWater Tower Research US Climate Virtual Investor Conference:..
04/12/202314:35GLOBEWater Tower Research US Climate Investor Conference Agenda..
30/11/202322:28EDGAR2Form 8-K - Current report
30/11/202322:24GLOBEAltimmune Announces Positive Topline Results from MOMENTUM..
07/11/202322:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:06EDGAR2Form 8-K - Current report
07/11/202313:00GLOBEAltimmune Announces Third Quarter 2023 Financial Results and..
31/10/202312:30GLOBEAltimmune to Report Third Quarter 2023 Financial Results and..
26/10/202314:15DJNAltimmune Gets FDA Fast-Track Designation for Pemvidutide in..
26/10/202313:30GLOBEAltimmune Granted Fast Track Designation by FDA for..
25/10/202313:30GLOBEAltimmune to Present New Data on the Anti-Inflammatory and..
17/10/202313:30GLOBEAltimmune to Participate at Two Upcoming Investor..
29/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202322:55EDGAR2Form 8-K - Current report
26/9/202313:30GLOBEAltimmune Announces Oral Presentation of Pemvidutide..
12/9/202313:30GLOBEAltimmune Announces Completion of Dosing in the Phase 2..
30/8/202313:30GLOBEAltimmune to Participate at Two Upcoming Investor..
16/8/202322:14EDGAR2Form ARS - Annual Report to Security Holders
16/8/202322:10EDGAR2Form DEF 14A - Other definitive proxy statements
16/8/202300:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:04EDGAR2Form 8-K - Current report
10/8/202313:00GLOBEAltimmune Announces Second Quarter 2023 Financial Results..
03/8/202313:30GLOBEAltimmune to Report Second Quarter 2023 Financial Results..

Dernières Valeurs Consultées

Delayed Upgrade Clock